Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study

Tessa Dieckman; Michael Schumann; Hanneke Beaumont; Hetty J. Bontkes; Frits Koning; Gerd Bouma; Valerie Byrnes; Jane McCarthy; Andra Neefjes-Borst; Christoph Loddenkemper; Jeroen van Bergen; Marlous op de Weegh; RCDII Tofacitinib Consortium

doi:10.1016/j.cgh.2024.05.022

Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study

Tessa Dieckman
, Michael Schumann
, Hanneke Beaumont
, Hetty J. Bontkes
, Frits Koning
, Gerd Bouma^*
, Valerie Byrnes
, Jane McCarthy
, Andra Neefjes-Borst
, Christoph Loddenkemper
, Jeroen van Bergen
, Marlous op de Weegh
, RCDII Tofacitinib Consortium

^*Corresponding author for this work

Leiden University Medical Center
Vrije Universiteit Amsterdam
Charité – Universitätsmedizin Berlin
University of Galway
Amsterdam UMC - Vrije Universiteit Amsterdam
Pathotres Gemeinschaftspraxis für Pathologie
Anna Ziekenhuis
University of Oslo
Leiden University
Saolta University Health Care Group
Oslo University Hospital

Research output: Contribution to journal › Short survey › Academic › peer-review

48 Downloads (Pure)

Original language	English
Pages (from-to)	2334-2336
Number of pages	3
Journal	Clinical gastroenterology and hepatology
Volume	22
Issue number	11
Early online date	2024
DOIs	https://doi.org/10.1016/j.cgh.2024.05.022
Publication status	Published - Nov 2024

Access to Document

10.1016/j.cgh.2024.05.022

Enduring-clinical-remission-in-refractory-celiac-disease-type-ii-with-tofacitinib.pdfFinal published version, 452 KBLicence: CC BY

Cite this

Dieckman, T., Schumann, M., Beaumont, H., Bontkes, H. J., Koning, F., Bouma, G., Byrnes, V., McCarthy, J., Neefjes-Borst, A., Loddenkemper, C., van Bergen, J., Weegh, M. O. D., & RCDII Tofacitinib Consortium (2024). Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study. Clinical gastroenterology and hepatology, 22(11), 2334-2336. https://doi.org/10.1016/j.cgh.2024.05.022

@article{a30ce1917bf64ad0a54c2003db1d4b87,

title = "Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study",

author = "Tessa Dieckman and Michael Schumann and Hanneke Beaumont and Bontkes, \{Hetty J.\} and Frits Koning and Gerd Bouma and Valerie Byrnes and Jane McCarthy and Andra Neefjes-Borst and Christoph Loddenkemper and \{van Bergen\}, Jeroen and Weegh, \{Marlous op de\} and \{RCDII Tofacitinib Consortium\} and Lundin, \{K. E. A.\}",

year = "2024",

month = nov,

doi = "10.1016/j.cgh.2024.05.022",

language = "English",

volume = "22",

pages = "2334--2336",

journal = "Clinical gastroenterology and hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "11",

}

Dieckman, T, Schumann, M, Beaumont, H , Bontkes, HJ, Koning, F, Bouma, G, Byrnes, V, McCarthy, J, Neefjes-Borst, A, Loddenkemper, C, van Bergen, J, Weegh, MOD & RCDII Tofacitinib Consortium 2024, 'Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study', Clinical gastroenterology and hepatology, vol. 22, no. 11, pp. 2334-2336. https://doi.org/10.1016/j.cgh.2024.05.022

TY - JOUR

T1 - Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib

T2 - An Open-Label Clinical Study

AU - Dieckman, Tessa

AU - Schumann, Michael

AU - Beaumont, Hanneke

AU - Bontkes, Hetty J.

AU - Koning, Frits

AU - Bouma, Gerd

AU - Byrnes, Valerie

AU - McCarthy, Jane

AU - Neefjes-Borst, Andra

AU - Loddenkemper, Christoph

AU - van Bergen, Jeroen

AU - Weegh, Marlous op de

AU - RCDII Tofacitinib Consortium

AU - Lundin, K. E. A.

PY - 2024/11

Y1 - 2024/11

UR - https://www.scopus.com/pages/publications/85198575726

U2 - 10.1016/j.cgh.2024.05.022

DO - 10.1016/j.cgh.2024.05.022

M3 - Short survey

C2 - 38821313

SN - 1542-3565

VL - 22

SP - 2334

EP - 2336

JO - Clinical gastroenterology and hepatology

JF - Clinical gastroenterology and hepatology

IS - 11

ER -

Enduring Clinical Remission in Refractory Celiac Disease Type II with Tofacitinib: An Open-Label Clinical Study

Access to Document

Other files and links

Cite this